The GLP-1 Forecast: Key Predictions for 2024
This event is now available on-demand. If you have previously registered for this event please click here and login using the email that you used to register.
Produced and Sponsored by:
GLP-1s, a class of drugs that reduce blood sugar and assist in weight loss, have completely reshaped how we approach and treat obesity, yet challenges remain for employers and employees alike. The majority of employers are still concerned about the short and long-term cost implications of GLP-1s – even when GLP-1s are covered, members are struggling to access the medications amid a prolonged global shortage. So where do we go from here?
Join this complimentary webcast to dive into what the future holds for medically assisted obesity treatment. You'll discover:
• GLP-1 trends going into 2024
• How those trends could influence an organization's health and benefits strategy
• Ways to get ahead of the GLP-1 cost and supply-demand curves
Can't attend? Register for the webcast and watch it on-demand after the live webcast.
Dr. Linda Anegawa | Chief of Medicine | Noom
Dr. Linda Anegawa's 20+ year clinical career includes academic primary care internal medicine, bariatrics, and leadership in the digital health startup space. In 2012, she began leading the development of weight loss and lifestyle medicine programs at a variety of healthcare entities. She is a graduate of the University of Pennsylvania's Perelman School of Medicine and completed residency at Stanford.
Jordan Galante | Director of National Accounts | Noom
Jordan Galante leads our Consultant and National Account relationships at Noom, including strategy and channel partnerships. Prior to joining Noom, she helped launch commercial divisions at previous Health Tech companies.